Video 1 October 2014

IFPMA 2014 interview series on ‘How Pharma is responding to the Ebola outbreak’


Faced with the current sudden outbreak of Ebola, the World Health Organization (WHO) consulted experts and researchers engaged in Ebola therapies and vaccines research and development (R&D) in 4-5 September 2014. They decided to expedite the development of two of the most advanced vaccines identified so far: One developed by GlaxoSmithKline in collaboration with the US National Institute of Allergy and Infectious Diseases. It uses a chimpanzee-derived adenovirus vector with an Ebola virus gene inserted. The second is developed by the Public Health Agency of Canada in Winnipeg in collaboration with the NewLink Genetics company. Beyond these two, Dr Olga Popova, Johnson & Johnson’s Crucell speaks in this interview about her company’s engagement in speeding up the development of their vaccine candidate against Ebola.


The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit

Learn more

Media Contact

Elliot Dunster